Online inquiry

IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10927MR)

This product GTTS-WQ10927MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10927MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9452MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ13244MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ13746MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ1432MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ACC-001
GTTS-WQ2561MR IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 479
GTTS-WQ14248MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ15885MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
GTTS-WQ2372MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 102
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW